Can Additional Drug Therapy Accelerate Response Time to Antidepressants

Depression Clinical Trial

Official title:

Can Additional Drug Therapy Accelerate Response Time to Antidepressants: A Double-blind, Placebo-controlled Randomization Research Study for Major Depression

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00221494
• Other study ID #: 00-09-045-11
• Status: Withdrawn
• Phase: Phase 4
• First received: September 13, 2005
• Last updated: May 29, 2015
• Start date: January 2004

Study information

• Verified date: June 2006
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Antidepressants are commonly prescribed and are effective for treating depression. However, they generally take 4-6 weeks for a therapeutic response. This study is evaluating whether simultaneous treatment with thyroid hormone or pindolol can decrease the response time ("getting better faster") in patients who are starting SSRI treatment.

Description:

Major depression is an illness with substantial personal and economic morbidity (Greenberg et al.1993) and antidepressants are the cornerstone of treatment. As antidepressants usually require 3-6 weeks of use before a response occurs, an effective antidepressant acceleration strategy would reduce the time of onset for an effective antidepressant response. This has significant clinical implications, as it could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life.

The goal of this study is to enhance our understanding of strategies that accelerate or produce a more rapid treatment response in depression. This could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life.

The study goals are: 1.) To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response (i.e. faster rate of improvement), 2.) To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can augment or enhance treatment response (i.e. greater reduction in depressive symptoms at end of study phase), adn 3.) To assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: June 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients, male and female, between the ages of 18 to 65

2. DSM-IV criteria for major depressive disorder

3. No prior SSRI medication treatment (if a patient has discontinued a non-SSRI medication for side effects, they will not be excluded)

4. Ability to be followed clinically for 6 weeks

5. Each patient must understand the nature of the study and must sign an informed consent form

Exclusion Criteria:

1. Severe suicidality (as defined by Beck Depression Inventory Question 9, responses 2 or 3)

2. Major Axis I mental illness other than major depressive disorder

3. Unstable medical health specifically cardiovascular disease, abnormal EKG, history of severe drug allergy, poorly controlled diabetes, and asthma (pindolol contraindication)

4. History of thyroid disease or abnormal TFT's (stage I or II)

5. Need for adjunctive antipsychotic use or additional benzodiazepine during the study

6. Pregnancy

7. Seizure disorder

8. A positive urine toxicology screen

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Drug:
• citalopram + tiodothyronine, or + pindolol, or + placebo

Locations

Country	Name	City	State
United States	UCLA Neuropsychiatric Institute	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Mark Frye	University of California, Los Angeles

Country where clinical trial is conducted

United States,